Engineered CD47 Protects T Cells for Enhanced Antitumour Immunity

Researchers administered anti-CD47 antibodies in combination with adoptively transferred T cells with the goal of enhancing antitumour efficacy but observed abrogated therapeutic benefit due to rapid macrophage-mediated clearance of T cells expressing CARs or engineered T cell receptors.